P/E ratio for Redhill Biopharma (RDHL)
P/E ratio as of April 2024 (TTM): -0.1122
According to Redhill Biopharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.112214. At the end of 2022 the company had a P/E ratio of -0.1167.
P/E ratio history for Redhill Biopharma from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.1167 | -90.5% |
| 2021 | -1.23 | -68.07% |
| 2020 | -3.85 | -17.6% |
| 2019 | -4.67 | 43.02% |
| 2018 | -3.26 | 58.79% |
| 2017 | -2.06 | -56.76% |
| 2016 | -4.75 | -25.58% |
| 2015 | -6.39 | -42.49% |
| 2014 | -11.1 | 52.5% |
| 2013 | -7.28 | 31.24% |
| 2012 | -5.55 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 14.7 | -13,160.85% | 🇫🇷 France |
 Merck MRK | 69.7 | -62,227.63% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.7 | -10,501.47% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -6.51 | 5,696.96% | 🇮🇱 Israel |
 Taro Pharmaceutical TARO | 69.2 | -61,750.33% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.